In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Notes offering nets $671.3mm for Exact Sciences

Executive Summary

Exact Sciences Corp. (molecular diagnostics for cancer) netted $671.3mm through the public sale of $690mm aggregate amount, including the overallotment, of its 1% senior notes due 2025. The notes bear interest at 1% and convert to common shares at a rate of 13.2569 shares per $1k principal amount, or $75.43. (The company's stock averaged $53.79 at the time of the offering.)
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Laboratory Testing Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies